Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy—expert opinion

Bernhard J. Steinhoff, William E. Rosenfeld, José M. Serratosa, Christian Brandt, Pavel Klein, Manuel Toledo, Gregory L. Krauss

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical trial results have demonstrated that adjunctive cenobamate (CNB) substantially decreases seizure frequency in adults with uncontrolled focal onset seizures with an acceptable and well-identified safety profile. This manuscript summarizes an expert panel's recommendations regarding optimized CNB treatment of epilepsies with focal onset seizures. Cenobamate, when slowly titrated to the target maintenance dose, represents an effective new antiseizure medication (ASM) with a comparatively high rate of seizure freedom relative to existing treatment options. This paper reviews selection of suitable CNB treatment candidates, realistic treatment expectations and goals, appropriate CNB target doses, and methods to mitigate or avoid potential adverse events. Cenobamate can be a promising therapeutic choice for adult people with epilepsy with focal onset seizures who do not reach adequate seizure control despite treatment with conventional ASMs.

Original languageEnglish (US)
Article number108270
JournalEpilepsy and Behavior
Volume123
DOIs
StatePublished - Oct 2021

Keywords

  • Cenobamate
  • Drug-resistant epilepsy
  • Focal onset seizure
  • Seizure freedom
  • Titration

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Fingerprint

Dive into the research topics of 'Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy—expert opinion'. Together they form a unique fingerprint.

Cite this